Is a PEGylated Protein Considered a Biobetter Biologic or Biosimilar Drug?
The FDA’s consideration of a biosimilar drug could open up biologic drug research. Learn how you can innovate with our PEGylation products!
The FDA’s consideration of a biosimilar drug could open up biologic drug research. Learn how you can innovate with our PEGylation products!
Nanolipoprotein particles (NLPs), which are mimetics of naturally occurring high-density lipoproteins (HDLs) present in the human body have been suggested as a new delivery platform for a range of therapeutics for cancer chemotherapy, heart disease, and infectious diseases. FDA approved drugs such as immunotherapeutic proteins, single-stranded DNA, small molecule drugs such as doxorubicin can be […]
Creative PEGWorks has collected hundreds of papers published in peer-reviewed journals citing the use of PEG derivatives for PEGylation of proteins, enzymes, antibodies, peptides, biologic, nucleic acids, nanoparticles, chips, surfaces, dendrimers, hydrogels, liposomes and micelles. These papers describe detailed procedures and chemistry reaction conditions as well as experiment characterization data for the use of PEGylation […]
A research group from the Republic of Korea developed poly(ethylene glycol)-conjugated hyaluronic acid nanoparticles (PEG-HANPs) with high tumor targetability. Doxorubicin (DOX) was chosen as the model anticancer drug and was effectively encapsulated into the mineralized nanoparticles. How PEGylated Drugs Impact Cancer Research “The most effective antitumor efficacy was observed for DOX-loaded PEG-HANPs. Overall, these results […]
Creative PEGWorks developed a series of amphiphilic, surfactant-like PEG derivatives and they are now available for purchase online. PEG surfactants and pegylated lipids can be used for drug delivery and formulation, to enhance drug solubility, improve bioavailability and pharmacokinetics, enable targeting cell receptors, and amplify imaging signals. PEGs in Drug Delivery & Formulation Successful examples […]
Researchers from the Massachusetts General Hospital and Harvard Medical School developed the novel, “PEG-like Nanoprobes,’’ with controllable pharmacokinetics and tunable fluorescence. The “PEG-like Nanoprobes’’ nanoparticles feature a unique design where a single PEG polymer surrounds a short fluorochrome and radiometal bearing peptide, and endows the resulting nanoprobe with pharmacokinetic control (based on the molecular weight […]
Researchers from the University of Washington and the Howard Hughes Medical Institute use an innovative computational design approach coupled with in-vitro-targeted evolution to produce a potent polypeptide inhibitor that triggers apoptosis of virus-infected cancer cells, suppresses tumor growth, and extends survival in a xenograft model of EBV-positive human lymphoma. How Designer Proteins Impact Cancer Research […]